NEW YORK (GenomeWeb) – T2 Biosystems announced after the close of the market today that it has begun a public offering of 3.5 million shares of its common stock.
The company also said it expects to grant the underwriters of the offering a 30-day option to buy an additional 525,000 shares at the public offering price. Goldman Sachs is acting as the book-running manager for the offering. Additional underwriters include Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.
T2's stock closed at $11.77 in Tuesday trade on the Nasdaq.
In September, T2 filed with the US Securities and Exchange Commission to sell up to $100 million of its common stock.